HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Myerowitz, R. Articles by Costigan, F. C. Search for Related Content PubMed PubMed Citation Articles by Myerowitz, R. Articles by Costigan, F. C. Social Bookmarking                      What's this?

J. Biol. Chem., Vol. 263, Issue 35, 18587-18589, Dec, 1988

The major defect in Ashkenazi Jews with Tay-Sachs disease is an insertion in the gene for the alpha-chain of beta-hexosaminidase

R Myerowitz and FC Costigan
Laboratory of Biochemistry and Metabolism, National Institute of Diabetes and Digestive and Kidney Diseases, Bethesda, Maryland 20892.

The Ashkenazi Jewish population is enriched for carriers of a fatal form of Tay-Sachs disease, an inherited disorder caused by mutations in the alpha-chain of the lysosomal enzyme, beta-hexosaminidase A. Until recently it was presumed that Tay-Sachs patients from this ethnic isolate harbored the same alpha-chain mutation. This was disproved by identification of a splice junction defect in the alpha-chain of an Ashkenazi patient which could be found in only 20-30% of the Ashkenazi carriers tested. In this study we have isolated the alpha-chain gene from an Ashkenazi Jewish patient, GM515, with classic Tay-Sachs disease who was negative for the splice junction defect. Sequence analysis of the promoter region, exon and splice junctions regions, and polyadenylation signal area revealed a 4-base pair insertion in exon 11. This mutation introduces a premature termination signal in exon 11 which results in a deficiency of mRNA in Ashkenazi patients. A dot blot assay was developed to screen patients and heterozygote carriers for the insertion mutation. The lesion was found in approximately 70% of the carriers tested, thereby distinguishing it as the major defect underlying Tay-Sachs disease in the Ashkenazi Jewish population.
CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this?

This article has been cited by other articles:

				D. C. Martin, B. L. Mark, B. L. Triggs-Raine, and M. R. Natowicz Evaluation of the Risk for Tay-Sachs Disease in Individuals of French Canadian Ancestry Living in New England Clin. Chem., March 1, 2007; 53(3): 392 - 398. [Abstract] [Full Text] [PDF]

				J. C. Rucker, B. E. Shapiro, Y. H. Han, A. N. Kumar, S. Garbutt, E. L. Keller, and R. J. Leigh Neuro-ophthalmology of late-onset Tay-Sachs disease (LOTS) Neurology, November 23, 2004; 63(10): 1918 - 1926. [Abstract] [Full Text] [PDF]

				K. S. Rajavel and E. F. Neufeld Nonsense-Mediated Decay of Human HEXA mRNA Mol. Cell. Biol., August 15, 2001; 21(16): 5512 - 5519. [Abstract] [Full Text] [PDF]

				T. Tanaka, T. Nakata, T. Oka, T. Ogawa, F. Okamoto, Y. Kusaka, K. Sohmiya, K. Shimamoto, and K. Itakura Defect in human myocardial long-chain fatty acid uptake is caused by FAT/CD36 mutations J. Lipid Res., May 1, 2001; 42(5): 751 - 759. [Abstract] [Full Text]

				Z. Cao, E. Petroulakis, T. Salo, and B. Triggs-Raine Benign HEXA Mutations, C739T(R247W) and C745T(R249W), Cause beta -Hexosaminidase A Pseudodeficiency by Reducing the alpha -Subunit Protein Levels J. Biol. Chem., June 6, 1997; 272(23): 14975 - 14982. [Abstract] [Full Text] [PDF]

				R Navon and R. Proia The mutations in Ashkenazi Jews with adult GM2 gangliosidosis, the adult form of Tay-Sachs disease Science, March 17, 1989; 243(4897): 1471 - 1474. [Abstract] [PDF]